细胞周期蛋白依赖激酶
细胞周期蛋白依赖激酶2
细胞周期蛋白依赖激酶4
癌症研究
激酶
临床试验
CDK抑制剂
背景(考古学)
乳腺癌
医学
癌症
肿瘤科
内科学
生物
细胞周期
生物化学
古生物学
作者
R. Gerosa,Rita De Sanctis,Flavia Jacobs,C. Benvenuti,Mariangela Gaudio,Giuseppe Saltalamacchia,Rosalba Torrisi,Giovanna Masci,Chiara Miggiano,Francesco Agustoni,Paolo Pedrazzoli,Armando Santoro,Alberto Zambelli
标识
DOI:10.1016/j.critrevonc.2024.104324
摘要
Aberrant cyclin-dependent kinase 2 (CDK2) activation has been identified as a main resistance mechanism to CDK4/6 inhibition in hormone-positive (HR+) breast cancer. Additionally, consistent preclinical evidence states its crucial role in MYC and CCNE1 overexpressed cancer survival, such as triple-negative breast cancers (TNBC), thus representing an appealing and relatively unexplored target treatment opportunity. Despite emerging initial results of novel CDK2 inhibitors (CDK2i) activity, a comprehensive outcomes collection is currently absent from the scientific literature. We aim to provide an overview of ongoing clinical trials involving CDK2i in the context of metastatic breast cancer (mBC), either as monotherapy or in combination with other agents. The review extends beyond CDK2i to encompass novel emerging CDK4 inhibitors, combined CDK2/4/6 inhibitors, and the well-known pan-CDK inhibitors including those specifically directed at CDK2. Delving into the results, we critically appraise the observed clinical efficacy and offer valuable insights into their potential impact and future applications.
科研通智能强力驱动
Strongly Powered by AbleSci AI